Evidence map›Paper›PMID 36831431›Full record

ArticleCancers2023

Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer.

Clelia Madeddu, Silvia Busquets, Clelia Donisi, Eleonora Lai, Andrea Pretta, Francisco Javier López-Soriano, Josep Maria Argilés, Mario Scartozzi, Antonio Macciò

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 4 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Clelia MadedduMedical Oncology Unit, "Azienda Ospedaliero Universitaria" of Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0001-8940-6987
Silvia BusquetsDepartament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain.ORCID 0000-0002-9319-3555
Clelia DonisiMedical Oncology Unit, "Azienda Ospedaliero Universitaria" of Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Eleonora LaiMedical Oncology Unit, "Azienda Ospedaliero Universitaria" of Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Andrea PrettaMedical Oncology Unit, "Azienda Ospedaliero Universitaria" of Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Francisco Javier López-SorianoDepartament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain.
Josep Maria ArgilésDepartament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain.
Mario ScartozziMedical Oncology Unit, "Azienda Ospedaliero Universitaria" of Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0001-5977-5546
Antonio MacciòGynecologic Oncology Unit, ARNAS G. Brotzu, Department of Surgical Sciences, University of Cagliari, 09100 Cagliari, Italy.
University of Cagliari · ITInstitut de Biomedicina de la Universitat de Barcelona

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitor (ICI)-based immunotherapy has significantly improved the survival of patients with advanced non-small cell lung cancer (NSCLC); however, a significant percentage of patients do not benefit from this approach, and predictive biomarkers are needed. Increasing evidence demonstrates that cachexia, a complex syndrome driven by cancer-related chronic inflammation often encountered in patients with NSCLC, may impair the immune response and ICI efficacy. Herein, we carried out a prospective study aimed at evaluating the prognostic and predictive role of cachexia with the related changes in nutritional, metabolic, and inflammatory parameters (assessed by the multidimensional miniCASCO tool) on the survival and clinical response (i.e., disease control rate) to ICI-based immunotherapy in patients with advanced NSCLC. We included 74 consecutive patients. Upon multivariate regression analysis, we found a negative association between IL-6 levels (odds ratio (OR) = 0.9036; 95%CI = 0.8408-0.9711;

Indexed as

cachexiaglasgow prognostic scoreIL-6immune checkpoint inhibitorimmunotherapyinflammationminiCASCONLRnon-small cell lung cancersarcopeniasurvival

Identifiers

PMID36831431
PMCPMC9953791
OpenAlexW4319763329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.